Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
S. Harrison Farber, Aladine A. Elsamadicy, Ahmet Fatih Atik, Carter M. Suryadevara, Pakawat Chongsathidkiet, Peter E. Fecci & John H. Sampson. (2017) The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion on Drug Safety 16:3, pages 277-287.
Read now
Read now
Joseph M. Ryan, Jeffrey S. Wasser, Adam J. Adler & Anthony T. Vella. (2016) Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy 16:5, pages 655-674.
Read now
Read now
Gheath Alatrash, Haroon Jakher, Patricia D Stafford & Elizabeth A Mittendorf. (2013) Cancer immunotherapies, their safety and toxicity. Expert Opinion on Drug Safety 12:5, pages 631-645.
Read now
Read now
Axel Hoos, Sylvia Janetzki & Cedrik M. Britten. (2012) Advancing the field of cancer immunotherapy. OncoImmunology 1:9, pages 1457-1459.
Read now
Read now
Articles from other publishers (31)
Yuying Dong, Mingming Zheng, Xiaoxuan Wang, Chenyue Yu, Tiantian Qin & Xuning Shen. (2023) High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy. BMC Cancer 23:1.
Crossref
Crossref
Joonatan Mattila, Silja Sormunen, Nelli Heikkilä, Ilkka P. Mattila, Jari Saramäki & T. Petteri Arstila. (2023) Analysis of thymic generation of shared T‐cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild‐type antigens. Cancer Medicine 12:12, pages 13486-13496.
Crossref
Crossref
Olamide Tosin Olaoba, Kehinde Sulaimon Ayinde, Olubodun Michael Lateef, Michael Olawale Akintubosun, Khadijat Ayodeji Lawal & Temitope Isaac Adelusi. (2023) Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPα-based cancer therapy. Critical Reviews in Oncology/Hematology 184, pages 103939.
Crossref
Crossref
M. Vindhya, M. N. Ramesh Bharadwaj, Kanthesh M. Basalingappa, T. S. Gopenath & Ashok Gnanasekaran. 2023. Targeted Cancer Therapy in Biomedical Engineering. Targeted Cancer Therapy in Biomedical Engineering
179
217
.
Yinghan Chan, Joycelin Zhu Xin Tan, Xin Wei Lim, Dinesh Kumar Chellappan & Kamal Dua. 2023. Synbiotics for the Management of Cancer. Synbiotics for the Management of Cancer
61
98
.
Rahela Zaman, Rowshan Ara Islam & Ezharul Hoque Chowdhury. (2022) Evolving therapeutic proteins to precisely kill cancer cells. Journal of Controlled Release 351, pages 779-804.
Crossref
Crossref
Matthew M. Gubin & Matthew D. Vesely. (2022) Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research 28:18, pages 3917-3928.
Crossref
Crossref
Yuanfei Lu, Na Feng, Yongzhong Du & Risheng Yu. (2022) Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma. Nanomaterials 12:16, pages 2832.
Crossref
Crossref
Eka Kvaratskhelia, Ketevani Kankava, Sandro Surmava & Elene Abzianidze. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
415
433
.
Adriana Petrazzuolo, Maria Perez-Lanzon, Isabelle Martins, Peng Liu, Oliver Kepp, Véronique Minard-Colin, Maria Chiara Maiuri & Guido Kroemer. (2021) Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death & Disease 12:8.
Crossref
Crossref
Meike Kohlruss, Katja Ott, Bianca Grosser, Moritz Jesinghaus, Julia Slotta-Huspenina, Alexander Novotny, Alexander Hapfelmeier, Thomas Schmidt, Matthias M. Gaida, Wilko Weichert & Gisela Keller. (2021) Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers 13:5, pages 1048.
Crossref
Crossref
Carolin Haeussler & Anne Assmus. (2021) Bridging the gap between invention and innovation: Increasing success rates in publicly and industry-funded clinical trials. Research Policy 50:2, pages 104155.
Crossref
Crossref
Izabela Karwacka, Łukasz Obołończyk, Sonia Kaniuka-Jakubowska & Krzysztof Sworczak. (2021) The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma. Biomedicines 9:2, pages 98.
Crossref
Crossref
AnjumMehmood Dhamani, HardikSanjeev Sheth, Susrita Bhattacharyya & ImranNisar Shaikh. (2021) Paradigm shift from palliation to cure in metastatic microsatellite high colorectal carcinoma with immune checkpoint inhibitors. Journal of Cancer Research and Therapeutics 17:6, pages 1552.
Crossref
Crossref
Salonee Martins, Purva Salvi, Sai Tejaswi Lavuri, Manjita Srivastava, Shalini Sakthivel, Muneesh Kumar Barman, Kailash Chand, Meenakshi Singh, Subash C. Sonkar & Prudhvilal Bhukya. 2021. Handbook of Research on Advancements in Cancer Therapeutics. Handbook of Research on Advancements in Cancer Therapeutics
42
88
.
Fatemeh Sadeghi, Ali Sanjari Moghaddam & Saeed Soleyman-Jahi. 2021. Cancer Immunology. Cancer Immunology
597
635
.
François-Emery Cotté, Paméla Voillot, Bryan Bennett, Bruno Falissard, Christophe Tzourio, Pierre Foulquié, Anne-Françoise Gaudin, Hervé Lemasson, Valentine Grumberg, Laura McDonald, Carole Faviez & Stéphane Schück. (2020) Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study. Journal of Medical Internet Research 22:9, pages e19694.
Crossref
Crossref
Yuanyuan Zhang & Zemin Zhang. (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology 17:8, pages 807-821.
Crossref
Crossref
Marc Buyse, Everardo D. Saad, Tomasz Burzykowski & Julien Péron. (2020) Assessing Treatment Benefit in Immuno-oncology. Statistics in Biosciences 12:2, pages 83-103.
Crossref
Crossref
Chang Hoon Lee, Jungsook Cho & Kyeong Lee. (2020) Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. Biomolecules & Therapeutics 28:2, pages 119-130.
Crossref
Crossref
Beth L Nordstrom, Mustafa Oguz, Bong Chul Chu, Mario Ouwens, Henrik-Tobias Arkenau & Alyssa B Klein. (2020) Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison. Journal of Comparative Effectiveness Research 9:3, pages 191-199.
Crossref
Crossref
M. Provencio, E. Carcereny & Á. Artal. (2019) Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clinical and Translational Oncology 21:11, pages 1464-1471.
Crossref
Crossref
Quoc-Viet Le, Geon Yang, Yina Wu, Ho Won Jang, Mohammadreza Shokouhimehr & Yu-Kyoung Oh. (2019) Nanomaterials for modulating innate immune cells in cancer immunotherapy. Asian Journal of Pharmaceutical Sciences 14:1, pages 16-29.
Crossref
Crossref
Antje Hoering, Brian Durie, Hongwei Wang & John Crowley. (2017) End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. Future Oncology 13:13, pages 1181-1193.
Crossref
Crossref
Axel Hoos. (2016) Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery 15:4, pages 235-247.
Crossref
Crossref
Sangeetha De & Linda Meredith. (2016) A unique multiattribute method to predict success of emerging drug targets. Drug Discovery Today 21:3, pages 385-394.
Crossref
Crossref
Pankita H. Pandya, Mary E. Murray, Karen E. Pollok & Jamie L. Renbarger. (2016) The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. Journal of Immunology Research 2016, pages 1-13.
Crossref
Crossref
Litao Zhang & Carl Decicco. 2014. Collaborative Innovation in Drug Discovery. Collaborative Innovation in Drug Discovery
31
56
.
Cristina Suárez, Rafael Morales-Barrera, Victor Ramos, Isaac Núñez, Claudia Valverde, Jacques Planas, Juan Morote, Xavier Maldonado & Joan Carles. (2014) Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC). BJU International 113:3, pages 367-375.
Crossref
Crossref
Jessica Marshall. (2014) Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries. Molecular and Clinical Oncology.
Crossref
Crossref
Francesca Kalli, Rodolfo Machiorlatti, Florinda Battaglia, Alessia Parodi, Giuseppina Conteduca, Francesca Ferrera, Michele Proietti, Samuele Tardito, Marina Sanguineti, Enrico Millo, Daniela Fenoglio, Raffaele De Palma, Giorgio Inghirami & Gilberto Filaci. (2013) Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. Journal of Translational Medicine 11:1.
Crossref
Crossref